首页> 美国卫生研究院文献>PLoS Clinical Trials >Development of a gastroretentive delivery system for acyclovir by 3D printing technology and its in vivo pharmacokinetic evaluation in Beagle dogs
【2h】

Development of a gastroretentive delivery system for acyclovir by 3D printing technology and its in vivo pharmacokinetic evaluation in Beagle dogs

机译:通过3D打印技术开发用于阿昔洛韦的胃滞留递送系统,并在比格犬中进行体内药代动力学评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Gastroretentive (GR) systems are designed to prolong gastric residence time to allow sustained absorption and improve the oral bioavailability of drugs with a narrow absorption window in the upper part of the gastrointestinal tract. The present study aimed to develop a GR system for acyclovir using 3D printing technology and evaluate its in vivo pharmacokinetics after oral administration in Beagle dogs. The system consisted of a gastro-floating device, which can float in the gastric fluid, prepared by a fused deposition modeling 3D printer and conventional acyclovir sustained-release (SR) tablet. The acyclovir SR tablet was inserted to the floating device to allow sustained release of the drug in the stomach. The buoyancy and sustained-release property of the developed GR system were determined using an in vitro dissolution test, in vivo pharmacokinetic study, and abdominal X-ray imaging in Beagle dogs. The in vivo dissolution profiles of the GR system were also predicted based on the in vivo pharmacokinetic data using a population pharmacokinetic (POP-PK) model. In the dissolution test, the sustained-release characteristic of the GR system was identified with a time corresponding to 80% dissolution (T80) of 2.52 h. Following oral administration of the GR system, the time to reach the maximum concentration (Tmax) of acyclovir was significantly prolonged, whereas the maximum concentration (Cmax) decreased and the area under the curve increased compared with those obtained after the administration of immediate-release and SR tablets, indicating prolonged absorption. By X-ray imaging, we showed that the developed GR system stayed in the stomach for more than 12 h. The POP-PK model successfully described the observed plasma concentration-time data and predicted the in vivo biphasic dissolution profiles of the GR system, which was significantly different from the in vitro dissolution. The developed GR system could be applied to various drugs and had great prospects in the design and development of novel controlled-release formulations.
机译:胃滞留(GR)系统旨在延长胃停留时间,以允许持续吸收并提高在胃肠道上部具有狭窄吸收窗口的药物的口服生物利用度。本研究旨在使用3D打印技术为阿昔洛韦开发GR系统,并在Beagle犬口服后评估其体内药代动力学。该系统由可漂浮在胃液中的胃漂浮装置组成,该装置由融合沉积模型3D打印机和常规的阿昔洛韦缓释(SR)片剂制备。将阿昔洛韦SR片剂插入浮动设备中,以使药物在胃中持续释放。使用体外溶出试验,体内药代动力学研究和Beagle犬腹部X射线成像,确定了发达的GR系统的浮力和缓释特性。还使用群体药代动力学(POP-PK)模型基于体内药代动力学数据预测了GR系统的体内溶出曲线。在溶出度测试中,确定了GR系统的缓释特性,其时间对应于80%溶出度(T80)为2.52小时。口服GR系统后,与立即释放相比,达到阿昔洛韦最大浓度(Tmax)的时间显着延长,而最大浓度(Cmax)降低且曲线下面积增加和SR片剂,表明吸收时间延长。通过X射线成像,我们显示已开发的GR系统在胃中停留了12小时以上。 POP-PK模型成功地描述了观察到的血浆浓度-时间数据,并预测了GR系统的体内双相溶出曲线,这与体外溶出显着不同。研制的GR系统可应用于多种药物,在新型控释制剂的设计和开发方面具有广阔的前景。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号